• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

byMichaela Dowling, MDandKiera Liblik
December 11, 2024
in Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant regimen significantly extended progression-free survival compared to palbociclib-fulvestrant alone.

2. The addition of inavolisib did not significantly increase the overall occurrence of adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Locally advanced or metastatic hormone receptor-positive breast cancer is driven by the estrogen receptor, cyclin-dependent kinase 4 and 6 (CDK4/6), and phosphatidylinositol 3-kinase (PI3K) pathways. Consequently, blocking these pathways simultaneously may offer an effective treatment strategy. Inavolisib is a selective inhibitor of the alpha isoform of the p110 subunit of PI3K and degrades proteins with mutations in this subunit. Prior research has shown that tumors with PIK3CA mutations are responsive to inavolisib, both alone and with other standard therapies. This study aimed to evaluate whether inavolisib, combined with palbociclib (a kinase inhibitor) and fulvestrant (an estrogen receptor antagonist), is superior to palbociclib-fulvestrant therapy alone in treating hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Patients treated with inavolisib showed significantly longer progression-free survival than those in the placebo group, and twice as many patients in the inavolisib group had an objective response to treatment compared to the placebo group. There were no significant differences in adverse event rates between groups. However, limitations included the use of only one of three approved CDK4/6 inhibitors, the exclusion of patients with type 1 or 2 diabetes, and the underrepresentation of Black patients. Additionally, few patients had prior treatment with a CDK4/6 inhibitor, leaving the impact of prior exposure on efficacy unclear. Nevertheless, the findings suggest that a regimen including inavolisib, palbociclib, and fulvestrant may be effective for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Improving the Outcome of Bad-Acting Hormone Receptor–Positive Breast Cancer

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

FDA approvedFor breast cancer: Wilserdly (giredestrant), Nov 16, 2026→

In-Depth [randomized controlled trial]: This phase three randomized controlled trial evaluated the efficacy and safety of adding inavolisib, a PI3Kα inhibitor, to a palbociclib-fulvestrant regimen in patients with PIK3CA-mutated advanced breast cancer. Eligible patients had hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer measurable by RECIST criteria, with disease progression or recurrence within one year of completing adjuvant endocrine therapy, fasting glucose levels below 126 mg/dL, and glycated hemoglobin below 6.0%. A total of 161 patients were randomized to the inavolisib-palbociclib-fulvestrant group (inavolisib group) and 164 to the palbociclib-fulvestrant group (placebo group). The median progression-free survival, the primary outcome, was 15.0 months in the inavolisib group, significantly longer than the 7.3 months in the placebo group (hazard ratio [HR], 0.43; 95% Confidence Interval [CI], 0.32-0.59; p<0.001). Subgroup analysis showed this consistent benefit of inavolisib across all subgroups except in patients over 65 years (HR, 0.96; 95% CI, 0.50-1.83) and those previously treated with an aromatase inhibitor and tamoxifen (HR, 1.17; 95% CI, 0.42-3.24). In addition, 58.4% of patients in the inavolisib group achieved an objective response to the treatment, compared to 25.0% of the patients in the placebo group (95% CI, 23.3-43.5). The median duration of response was 18.4 months in the inavolisib group and 9.6 months in the placebo group (HR, 0.57; 95% CI, 0.33-0.99). Although the overall rate of adverse events was similar between groups, serious adverse events occurred more frequently in the inavolisib group (24.1% vs. 10.5% in the placebo group). Adverse events led to the discontinuation of at least one trial agent in 6.8% of patients in the inavolisib group, compared to 0.6% in the placebo group. Overall, these findings suggest that adding inavolisib to a palbociclib-fulvestrant regimen may offer clinical benefits for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast CancerHer2HER2-negative advanced breast cancerHER2-negative breast cancerInavolisiboncologyPIK3CA-mutatedrandomized controlled trial
Previous Post

Tranexamic acid reduces life-threatening postpartum bleeding

Next Post

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

RelatedReports

A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
A middle-aged woman looks thoughtfully at an abstract representation of cells and a statin pill, symbolizing breast cancer and medication usage.
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Next Post
#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

#VisualAbstract: Twice-Yearly Lenacapavir is Effective for Human Immunodeficiency Virus Prevention in Men and Gender-Diverse Persons

Maternal cell-free DNA sequencing superior to standard aneuploidy screening [CARE Study]

Australian couple-based genetic screening program feasible and accepted

Reduced pneumococcal vaccine schedules non-inferior to WHO recommendations

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
  • Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.